Login / Signup

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.

Ali HajjarMehmet A ErgunOguzhan AlagozMurtuza Rampurwala
Published in: PloS one (2019)
TH is cost-effective for all age groups in the base case scenario and in the sensitivity analysis. In order to reduce the parameter uncertainty, clinical trials with longer follow-up times are needed.
Keyphrases
  • early stage
  • positive breast cancer
  • clinical trial
  • lymph node
  • sentinel lymph node
  • squamous cell carcinoma
  • randomized controlled trial
  • radiation therapy
  • metastatic breast cancer
  • phase iii
  • study protocol